Tharimmune, Inc. has reported significant financial developments in its latest 10-K filing, reflecting a strategic pivot from biotechnology operations to a focus on digital asset treasury management, particularly involving Canton Coin (CC). For the fiscal year ending December 31, 2025, the company recorded a net loss of $42.1 million, a substantial increase from a loss of $12.2 million in the previous year. This shift in financial performance is attributed to the company's new focus on digital assets, which included an unrealized loss of $22 million from its digital asset holdings.
The company's total operating expenses rose to $20.1 million in 2025, up from $12.4 million in 2024, driven primarily by a 182% increase in general and administrative expenses, which reached $17 million. This increase was largely due to higher personnel costs, investor relations expenses, and stock-based compensation. In contrast, research and development expenses decreased by 52% to $3.1 million, reflecting the completion of certain clinical trials and a strategic reduction in R&D activities as the company transitions to its new business model.
In terms of operational changes, Tharimmune completed a series of financing transactions, including a private placement offering in November 2025 that raised approximately $545 million. This capital infusion is intended to support the company's digital asset treasury strategy and validator operations on the Canton Network. The company has also established an at-the-market equity program and a shelf registration statement to enhance its liquidity and capital access.
As of December 31, 2025, Tharimmune reported an accumulated deficit of $72.8 million and indicated that it expects to continue incurring losses in the foreseeable future. The company has a total of 12 full-time employees and is not currently involved in any legal proceedings that could materially affect its financial condition. Looking ahead, Tharimmune aims to leverage its digital asset strategy to enhance its market position, although it acknowledges the inherent risks associated with the volatility of digital assets and the regulatory landscape surrounding them.
About Tharimmune, Inc.
Tharimmune is a biotech company focused on developing therapies for inflammatory and immunologic conditions with high unmet needs. Its pipeline includes novel biologics, bispecific antibodies, and innovative delivery systems targeting liver-related pruritus, cancer, and immune checkpoints. The company leverages proprietary technologies, strategic collaborations, and a clinical-stage portfolio to address complex diseases, aiming to improve treatment efficacy and patient outcomes in high-value therapeutic areas.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.